India, Nov. 22 -- CARsgen Therapeutics Holdings Limited (2171.HK) reported positive early clinical results for CT1182 (KJ-C2529), its investigational CD19/CD20-targeting in vivo CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
As of October 31, 2026, six patients had been enrolled in the dose-escalation study, including five patients with diffuse large B-cell lymphoma (DLBCL) and one patient with blastoid mantle cell lymphoma (MCL). The patients had advanced Stage IV disease and had received a median of three prior lines of treatment.
With a median follow-up of about 3.2 months, the therapy demonstrated encouraging anti-tumor activity. Among the six evaluable patients, three achieved a c...